Clearbridge BioMedics wins Asian Entrepreneurship Award in Japan
Clearbridge BioMedics has won the 2012 Asian Entrepreneurship awards, which was held from 9-11 May 2012 in Kashiwanoha, Chiba Prefecture in Japan. A total of 18 start-up companies, from 12 Asian countries presented their business plans at this inaugural business competition. Clearbridge BioMedics impressed the judges with its ClearCell™ System. This is a cell-based invitro diagnostic device that can isolate and retrieve intact and viable circulating tumour cells from blood. Clearbridge BioMedics, which was the only Singaporean company to participate, took home the 3 million yen (approximately SGD 47,000) prize money along with three years of free tenancy at the Tokatsu Techno Plaza in Chiba Prefecture. Clearbridge BioMedics is a spin-off company from the Faculty of Engineering, National University of Singapore.
“We are delighted and honoured to win the inaugural Asian Entrepreneurship Awards. Participating in this event was a great experience for us. We were able to network and present to an audience, including venture capitalists, entrepreneurs and potential partners. Japan is a very important market for us, winning this award will be a launch pad for us to bring the technology there.” said Dr Andrew Wu, Project Director Clearbridge BioMedics.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.